Voyager CSO granted RSUs and 154k stock options

Voyager Therapeutics Chief Scientific Officer equity awards: Todd Alfred Carter received 33,000 restricted stock units and a stock option for 154,000 shares of Voyager Therapeutics common stock on February 6, 2026.

Rhea-AI Filing Summary

Voyager Therapeutics Chief Scientific Officer equity awards: Todd Alfred Carter received 33,000 restricted stock units and a stock option for 154,000 shares of Voyager Therapeutics common stock on February 6, 2026. The RSUs vest over three years and the option, with a $3.68 exercise price, vests monthly over four years, both based on continued service.

Insider Trade Summary

Grant/Award: 187,000 shares

Grant/Award 2 txns

Insider Carter Todd Alfred

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	154,000	$0.00	$0.00
Grant/Award	Common Stock	33,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 154,000 contracts (Direct); Common Stock — 156,718 shares (Direct)

Footnotes (2)

1. F1. Consists of shares of common stock issuable under an aggregate of 33,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
2. F2. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did VYGR Chief Scientific Officer Todd Carter report?

Todd Carter reported receiving 33,000 restricted stock units and a stock option for 154,000 Voyager Therapeutics shares. Both awards were granted on February 6, 2026 under the company’s 2025 Stock Incentive Plan and vest over multi‑year schedules tied to continued service.

How many Voyager Therapeutics (VYGR) RSUs were granted to Todd Carter?

Todd Carter was granted 33,000 restricted stock units of Voyager Therapeutics common stock. Each RSU converts into one share upon vesting. The RSUs vest in three equal annual installments starting one year after the February 6, 2026 grant date, contingent on continued service.

What are the terms of Todd Carter’s VYGR stock option grant?

Todd Carter received a stock option for 154,000 Voyager Therapeutics shares at a $3.68 exercise price. The option vests over four years, with 1/48th of the underlying shares vesting monthly beginning one month after February 6, 2026, subject to continued service.

How many Voyager Therapeutics shares does Todd Carter own after this Form 4?

Following the reported RSU grant, Todd Carter beneficially owns 156,718 shares of Voyager Therapeutics common stock directly. This figure reflects his holdings after the February 6, 2026 award of 33,000 restricted stock units reported in the filing.

Are Todd Carter’s Voyager Therapeutics equity awards time-vested?

Yes. The 33,000 RSUs vest in three equal annual tranches over three years, starting one year after February 6, 2026. The 154,000-share stock option vests in 48 equal monthly installments over four years from the same grant date, conditioned on continued service.

Under which plan were Todd Carter’s VYGR RSUs and options granted?

Both the 33,000 restricted stock units and the 154,000-share stock option were granted under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. This plan governs the terms, including vesting schedules and service conditions, for the reported equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 04:32 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carter Todd Alfred

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		A		33,000(1)	A	$0.00	156,718	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.68	02/06/2026		A		154,000		(2)	02/06/2036	Common Stock	154,000	$0.00	154,000	D

Explanation of Responses:

1. Consists of shares of common stock issuable under an aggregate of 33,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

2. This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

	/s/ Gregory Shiferman, as Attorney-in-Fact for Todd Alfred Carter	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.